Baxter International BAX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Healthcare Systems & Technologies | $705M+0.1% | $827M+5.5% | $773M+2.8% | $767M+2.5% | $704M+5.5% | |
| Medical Products & Therapies | $1.29B+1.8% | $1.39B+5.6% | $1.33B-1.0% | $1.32B-0.2% | $1.26B+2.7% | |
| Pharmaceuticals | $621M+6.9% | $668M+3.9% | $632M+7.5% | $612M+1.7% | $581M+0.5% | |
| Net Sales by Product | ||||||
| Advanced Surgery | $304M+13.4% | $328M+12.3% | $306M+12.5% | $296M+6.9% | $268M+1.9% | |
| Care & Connectivity Solutions | $435M+1.9% | $537M+6.5% | $473M+3.7% | $474M+4.9% | $427M+6.2% | |
| Drug Compounding | $320M+30.1% | $316M+21.5% | $299M+12.0% | $280M+7.3% | $246M-1.6% | |
| Front Line Care | $270M-2.5% | $290M+3.6% | $300M+1.4% | $293M-1.0% | $277M+4.5% | |
| Infusion Therapies & Technologies | $981M-1.3% | $1.06B+3.7% | $1.02B-4.4% | $1.02B-2.0% | $994M+2.9% | |
| Injectables & Anesthesia | $301M-10.1% | $352M-8.1% | $333M+3.7% | $332M-2.6% | $335M+2.1% | |
| Net Sales by Geography | ||||||
| International | $1.27B+11.5% | $1.42B+14.4% | $1.29B+7.7% | $1.27B+6.0% | $1.14B-0.6% | |
| United States | $1.44B-3.7% | $1.55B+2.8% | $1.54B+2.9% | $1.54B+2.9% | $1.49B+10.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Baxter International break its business down?
- Baxter International (BAX) reports net sales by business across 3 parts — Healthcare Systems & Technologies, Medical Products & Therapies and Pharmaceuticals. Each is extracted from the segment footnotes and tracked over time.
- Where does Baxter International's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Baxter International's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
